KPL3,520.00

Kwality Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation10.614.9
Changes in Working Capital
+ Inventories-36.0-33.0
Cash from Operating Activities
Profit Before Tax (per I/S)161.725.831.5
Cash from Operations (pre-tax)104.448.3
Cash from Operating Activities63.142.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)55.247.729.8
+ Disp of Fixed Assets0.01.94.1
Cash from Investing Activities-63.0-48.4-26.4
Cash from Financing Activities
+ Proceeds from Borrowings14.44.1
+ Repayment of Borrowings12.37.011.3
+ Interest Paid2.96.010.2
Cash from Financing Activities5.71.0-17.4
Net Changes in Cash5.7-5.3-0.8
Reference Items
EBITDA171.760.366.6
EBITDA Margin %37.6524.0221.69
Free Cash Flow (CFO − Capex)7.9-5.5
Cash Flow to Net Income0.53
Cash Paid for Interest2.96.010.2
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.